about
Monoaminergic and Histaminergic Strategies and Treatments in Brain DiseasesLocus coeruleus cellular and molecular pathology during the progression of Alzheimer's disease.Expression of cerebral serotonin related to anxiety-like behaviors in C57BL/6 offspring induced by repeated subcutaneous prenatal exposure to low-dose lipopolysaccharideMolecular Mechanisms Underlying Neuroprotective Effect of Intranasal Administration of Human Hsp70 in Mouse Model of Alzheimer's Disease.Quantifying the accretion of hyperphosphorylated tau in the locus coeruleus and dorsal raphe nucleus: the pathological building blocks of early Alzheimer's disease.A clinicopathological approach to the diagnosis of dementia.Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs.Multi-Target Screening and Experimental Validation of Natural Products from Selaginella Plants against Alzheimer's Disease.Updating neuropathology and neuropharmacology of monoaminergic systemsNeuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms.MicroRNA Expression in the Locus Coeruleus, Entorhinal Cortex, and Hippocampus at Early and Middle Stages of Braak Neurofibrillary Tangle Pathology.Locus coeruleus at asymptomatic early and middle Braak stages of neurofibrillary tangle pathology.Alzheimer's Disease: The Alternative Serotonergic Hypothesis of Cognitive Decline.Three-dimensional analysis of synapses in the transentorhinal cortex of Alzheimer's disease patients.Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies?Locus coeruleus complex of the family Delphinidae.Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease.Altered Regulation of KIAA0566, and Katanin Signaling Expression in the Locus Coeruleus With Neurofibrillary Tangle Pathology.A Closer Look into the Role of Protein Tau in the Identification of Promising Therapeutic Targets for Alzheimer's DiseaseBrainstem Imaging in Alzheimer's Disease: Potential for Biomarker Development
P2860
Q28066691-00D8AD41-F068-40E3-9993-B8C488C6BA79Q30835713-2F727B63-C263-4B85-A76B-5A6E94B3AED6Q33834738-9FA1B1CE-E40A-44FF-9634-E5E3B166BD24Q38651368-B08E320A-AA71-48F2-9920-F8BA26D6AD87Q39002052-BBD19F0E-FAC5-4786-8864-9688B18C0475Q39434968-8B0E5102-DC4F-4D67-A079-82C8A441DE9EQ39438767-07F92696-F04E-4D82-93A9-555B7322A6BCQ41547446-08AEFDAF-C545-461F-9305-3D38F3287A7FQ42577060-1A3E1E76-DB7C-4275-BB6A-6A514927A813Q42655602-B6C28FB6-625A-41CE-A105-67552350F306Q47778002-A165FFD6-A6EE-4286-897F-E1822A7A6C51Q47986956-C035101E-6899-491A-9B9D-9AF74D3E8AB1Q49562614-D80310FF-FDD6-49D0-BBEF-987DAE5F3316Q50533053-08A9656E-9339-41BA-8E85-9897891675EFQ52315334-8F1B8824-0915-44DD-9DC2-ADF4D3307F02Q52332909-D8B547F3-EF8E-459F-8D87-6300CCF1A3A0Q55003565-865D47AE-B36F-4E83-8FDD-03503F7C335EQ55172664-964C2303-2194-4FBD-8405-F466DEF0F60CQ57927766-343E50EC-A318-41E0-A544-BE9FE277E083Q58750830-B420191D-26F9-43B9-9FCA-AA2222823B31
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Monoaminergic neuropathology in Alzheimer's disease.
@en
type
label
Monoaminergic neuropathology in Alzheimer's disease.
@en
prefLabel
Monoaminergic neuropathology in Alzheimer's disease.
@en
P2093
P2860
P50
P1476
Monoaminergic neuropathology in Alzheimer's disease.
@en
P2093
Claude M Wischik
Danira Bažadona
Patrick R Hof
Rohan de Silva
Selina Wray
P2860
P304
P356
10.1016/J.PNEUROBIO.2016.04.001
P50
P577
2016-04-12T00:00:00Z